Calixarene-modified Albumin for Stoichiometric Delivery of Multiple Drugs in Combination-chemotherapy

Overview

Journal Theranostics

Date 2022 Jun 6

PMID 35664058

Authors

Ying Wang

Zhanzhan Zhang

Xinzhi Zhao

Lina Xu

Yadan Zheng

Hua-Bin Li

Dong-Sheng Guo

Linqi Shi

Yang Liu

Affiliations

Soon will be listed here.

Abstract

In combination chemotherapy, the molar ratio of drugs is a critical parameter that determines the synergistic effects. However, most co-delivery vectors are incapable of maintaining the optimal molar ratio of drugs throughout the delivery process. Herein, a calixarene-modified albumin (CaMA), which can co-deliver multiple drugs with precise control of the drug ratio, is presented. CaMA was prepared by chemically conjugating multiple sulfonate azocalix[4]arenes (SAC4A) onto the surface of bovine serum albumin (BSA). The precise drug loading and synchronous drug release were measured using fluorescence spectroscopy. Mouse tumor cell 4T1 and 4T1-bearing mice were used to evaluate the combined effects of mitomycin C (MMC) and doxorubicin (DOX) and . With multiple hypoxia-responsive calixarenes conjugated onto a single albumin molecule, CaMA achieved precise drug loading and synchronous release of multiple drugs into the tumor microenvironment. This unique drug loading and release mechanism ensures that CaMA maintains the drug ratio from the initial drug loading to the release site, providing a solid foundation for multi-drug combination therapy with the goal of achieving predictable therapeutic outcomes . The delivery of the model drug combination MMC and DOX at a prescreened ratio via CaMA achieved significantly enhanced tumor suppression and reduced systemic toxicity. This stoichiometric delivery feature makes CaMA a powerful tool for the development of combination chemotherapy and personalized medications for cancer treatment.

Citing Articles

Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy.

Wang W, Yao S, Luo J, Ding C, Huang Q, Yang Y Nat Commun. 2025; 16(1):596.

PMID: 39799105 PMC: 11724902. DOI: 10.1038/s41467-025-55905-y.

Recent Advances in Calixarene-Based Fluorescent Sensors for Biological Applications.

Marcos P, Berberan-Santos M Sensors (Basel). 2024; 24(22).

PMID: 39598958 PMC: 11597938. DOI: 10.3390/s24227181.

Supramolecular Nano-Tracker for Real-Time Tracking of Drug Release and Efficient Combination Therapy.

Chen X, Chen F, Lu Y, Li Q, Li S, Zheng C Adv Sci (Weinh). 2024; 11(36):e2404731.

PMID: 39072943 PMC: 11423228. DOI: 10.1002/advs.202404731.

Synthetic Receptors for Early Detection and Treatment of Cancer.

Davis F, Higson S Biosensors (Basel). 2023; 13(11).

PMID: 37998127 PMC: 10669836. DOI: 10.3390/bios13110953.

Recent Advances in Supramolecular-Macrocycle-Based Nanomaterials in Cancer Treatment.

Pan Z, Zhao X, Li Q, Zhang Z, Liu Y Molecules. 2023; 28(3).

PMID: 36770907 PMC: 9920387. DOI: 10.3390/molecules28031241.

References

Zhang T, Li J, Li H, Guo D . Deep Cavitand Calixarene-Solubilized Fullerene as a Potential Photodynamic Agent. Front Chem. 2021; 9:710808. PMC: 8327297. DOI: 10.3389/fchem.2021.710808. View

Feng C, Zhang H, Chen J, Wang S, Xin Y, Qu Y . Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer. Int J Pharm. 2019; 560:191-204. DOI: 10.1016/j.ijpharm.2019.02.009. View

Wan X, Min Y, Bludau H, Keith A, Sheiko S, Jordan R . Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer. ACS Nano. 2018; 12(3):2426-2439. PMC: 5960350. DOI: 10.1021/acsnano.7b07878. View

Zhou J, Yu G, Huang F . Supramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future. Chem Soc Rev. 2017; 46(22):7021-7053. DOI: 10.1039/c6cs00898d. View

Chen Y, Zhang W, Huang Y, Gao F, Sha X, Fang X . Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. Int J Pharm. 2015; 488(1-2):44-58. DOI: 10.1016/j.ijpharm.2015.04.048. View

Zheng Z, Yu H, Geng W, Hu X, Wang Y, Li Z . Guanidinocalix[5]arene for sensitive fluorescence detection and magnetic removal of perfluorinated pollutants. Nat Commun. 2019; 10(1):5762. PMC: 6917741. DOI: 10.1038/s41467-019-13775-1. View

Zhang T, Zhang Z, Yue Y, Hu X, Huang F, Shi L . A General Hypoxia-Responsive Molecular Container for Tumor-Targeted Therapy. Adv Mater. 2020; 32(28):e1908435. DOI: 10.1002/adma.201908435. View

Goldman A, Kulkarni A, Kohandel M, Pandey P, Rao P, Natarajan S . Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. ACS Nano. 2016; 10(6):5823-34. DOI: 10.1021/acsnano.6b00320. View

Zhu L, Guo Y, Qian Q, Yan D, Li Y, Zhu X . Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer. Angew Chem Int Ed Engl. 2020; 59(41):17944-17950. DOI: 10.1002/anie.202006895. View

10.

Pusuluri A, Krishnan V, Lensch V, Sarode A, Bunyan E, Vogus D . Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate. Angew Chem Int Ed Engl. 2018; 58(5):1437-1441. DOI: 10.1002/anie.201812650. View

11.

Geng W, Sessler J, Guo D . Supramolecular prodrugs based on host-guest interactions. Chem Soc Rev. 2020; 49(8):2303-2315. DOI: 10.1039/c9cs00622b. View

12.

Yin Q, Pan A, Chen B, Wang Z, Tang M, Yan Y . Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy. Nat Commun. 2021; 12(1):2385. PMC: 8062465. DOI: 10.1038/s41467-021-22678-z. View

13.

Pusuluri A, Krishnan V, Wu D, Wyatt Shields 4th C, Wang L, Mitragotri S . Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin. Bioeng Transl Med. 2019; 4(2):e10129. PMC: 6584462. DOI: 10.1002/btm2.10129. View

14.

Hu X, Gao L, Mosel S, Ehlers M, Zellermann E, Jiang H . From Supramolecular Vesicles to Micelles: Controllable Construction of Tumor-Targeting Nanocarriers Based on Host-Guest Interaction between a Pillar[5]arene-Based Prodrug and a RGD-Sulfonate Guest. Small. 2018; 14(52):e1803952. DOI: 10.1002/smll.201803952. View

15.

Yang Z, Zhao L, Wang X, He Z, Wang Y . Ratiometric Delivery of Mitoxantrone and Berberine Co-encapsulated Liposomes to Improve Antitumor Efficiency and Decrease Cardiac Toxicity. AAPS PharmSciTech. 2021; 22(1):46. DOI: 10.1208/s12249-020-01910-x. View

16.

Meng F, Wang J, Ping Q, Yeo Y . Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations. Nano Lett. 2019; 19(3):1479-1487. PMC: 6417971. DOI: 10.1021/acs.nanolett.8b04017. View

17.

Wang H, Xue K, Yang Y, Hu H, Xu J, Zhang X . In Situ Hypoxia-Induced Supramolecular Perylene Diimide Radical Anions in Tumors for Photothermal Therapy with Improved Specificity. J Am Chem Soc. 2022; 144(5):2360-2367. DOI: 10.1021/jacs.1c13067. View

18.

Choi J, Shim M, Yang S, Hwang H, Cho H, Kim J . Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy. ACS Nano. 2021; 15(7):12086-12098. DOI: 10.1021/acsnano.1c03416. View

19.

Zhou F, Wang P, Peng Y, Zhang P, Huang Q, Sun W . Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy. Angew Chem Int Ed Engl. 2019; 58(34):11661-11665. DOI: 10.1002/anie.201903807. View

20.

Kolishetti N, Dhar S, Valencia P, Lin L, Karnik R, Lippard S . Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010; 107(42):17939-44. PMC: 2964221. DOI: 10.1073/pnas.1011368107. View